WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530335
CAS#: 5108-96-3
Description: MUN 08963, also known as Pyrrolidinedithiocarbamate ammonium, also known as PDTC, is a nuclear factor κB (NF-κB) inhibitor. Pyrrolidinedithiocarbamate attenuates bleomycin-induced pulmonary fibrosis in rats. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity. Pyrrolidinedithiocarbamate inhibits NF-kappaB activation and IL-8 production in intestinal epithelial cells. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to Hodoodo Chemical Nomenclature (see web page: https://www.hodoodo.com/page/naming).
Hodoodo Cat#: H530335
Name: MUN 08963
CAS#: 5108-96-3
Chemical Formula: C5H12N2S2
Exact Mass: 0.00
Molecular Weight: 164.285
Elemental Analysis: C, 36.56; H, 7.36; N, 17.05; S, 39.03
Synonym: Pyrrolidinedithiocarbamate ammonium; Ammonium 1-Pyrrolidinecarbodithioate. PDTC. APDC.; MUN 08963; MUN-08963; MUN08963
IUPAC/Chemical Name: ammonium pyrrolidine-1-carbodithioate
InChi Key: MDDIUTVUBYEEEM-UHFFFAOYSA-N
InChi Code: InChI=1S/C5H9NS2.H3N/c7-5(8)6-3-1-2-4-6;/h1-4H2,(H,7,8);1H3
SMILES Code: [S-]C(N1CCCC1)=S.[NH4+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 164.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Zaafan MA, Zaki HF, El-Brairy AI, Kenawy SA. Pyrrolidinedithiocarbamate attenuates bleomycin-induced pulmonary fibrosis in rats: Modulation of oxidative stress, fibrosis, and inflammatory parameters. Exp Lung Res. 2016 Oct 31:1-9. [Epub ahead of print] PubMed PMID: 27797599.
2: Yilmaz E, Soylak M. Switchable polarity solvent for liquid phase microextraction of Cd(II) as pyrrolidinedithiocarbamate chelates from environmental samples. Anal Chim Acta. 2015 Jul 30;886:75-82. doi: 10.1016/j.aca.2015.06.021. PubMed PMID: 26320638.
3: Montagner D, Sanz Miguel PJ. Unique Pt5 metallacycle: [Pt(II)Cl(pyrrolidinedithiocarbamate)]5. Dalton Trans. 2011 Nov 7;40(41):10809-11. doi: 10.1039/c1dt11475a. PubMed PMID: 21901224.
4: Wei G, Lin M, Cai Z, Huang H. Cytomegalovirus infection in mesenchymal stem cells and their activation could be enhanced by nuclear factor-κB inhibitor pyrrolidinedithiocarbamate in vitro. Transplant Proc. 2011 Jun;43(5):1944-9. doi: 10.1016/j.transproceed.2010.12.053. PubMed PMID: 21693305.
5: Song XQ, Li WQ, Jiang CD, Yang YF, Zhong ZX, Lü LX. [Effect of pyrrolidinedithiocarbamate on neural developmental disorder of adult offspring with maternal systemic exposure to Poly(I:C) during pregnancy]. Zhonghua Yi Xue Za Zhi. 2011 Feb 22;91(7):485-90. Chinese. PubMed PMID: 21418982.
6: Taruki M, Wakui T, Nukatsuka I, Ohzeki K. Determination of tin by resin-suspension electrothermal atomic absorption spectrometry after enrichment as the complex with ammonium pyrrolidinedithiocarbamate. Anal Sci. 2007 Dec;23(12):1435-8. PubMed PMID: 18071232.
7: Laghari AJ, Khuhawar MY, Zardari LA. Capillary gas chromatographic analysis of pyrrolidinedithiocarbamate metal chelates. J Sep Sci. 2007 Nov;30(16):2727-32. PubMed PMID: 17924369.
8: Houserová P, Matejícek D, Kubán V. High-performance liquid chromatographic/ion-trap mass spectrometric speciation of aquatic mercury as its pyrrolidinedithiocarbamate complexes. Anal Chim Acta. 2007 Jul 23;596(2):242-50. PubMed PMID: 17631102.
9: Hagar HH, El-Medany A, El-Eter E, Arafa M. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol. 2007 Jan 5;554(1):69-77. PubMed PMID: 17112501.
10: Bach SP, Williamson SE, O'Dwyer ST, Potten CS, Watson AJ. Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut. Br J Cancer. 2006 Jul 3;95(1):35-41. PubMed PMID: 16804527; PubMed Central PMCID: PMC2360501.
11: Malaguarnera L, Pilastro MR, Vicari L, Dimarco R, Manzella L, Palumbo G, Messina A. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity. Cancer Invest. 2005;23(5):404-12. PubMed PMID: 16193640.
12: Menezes DC, Vieira FT, de Lima GM, Porto AO, Cortés ME, Ardisson JD, Albrecht-Schmitt TE. Tin(IV) complexes of pyrrolidinedithiocarbamate: synthesis, characterisation and antifungal activity. Eur J Med Chem. 2005 Dec;40(12):1277-82. PubMed PMID: 16139393.
13: El Eter E, Hagar HH, Al-Tuwaijiri A, Arafa M. Nuclear factor-kappaB inhibition by pyrrolidinedithiocarbamate attenuates gastric ischemia-reperfusion injury in rats. Can J Physiol Pharmacol. 2005 Jun;83(6):483-92. PubMed PMID: 16049548.
14: Arima N, Arimura K, Tokito Y, Sakaki Y, Matsushita K, Orihara K, Akimoto M, Ozaki A, Kukita T, Hagiwara T, Hamada H, Tei C. HTLV-I Tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells. Exp Hematol. 2004 Feb;32(2):195-201. PubMed PMID: 15102481.
15: Malaguarnera L, Pilastro MR, DiMarco R, Scifo C, Renis M, Mazzarino MC, Messina A. Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate. Apoptosis. 2003 Oct;8(5):539-45. PubMed PMID: 14601560.
16: Malaguarnera L, Quan S, Pilastro MR, Abraham NG, Kappas A. Diminished heme oxygenase potentiates cell death: pyrrolidinedithiocarbamate mediates oxidative stress. Exp Biol Med (Maywood). 2003 May;228(5):459-65. PubMed PMID: 12709569.
17: Porcile C, Stanzione S, Piccioli P, Bajetto A, Barbero S, Bisaglia M, Bonavia R, Florio T, Schettini G. Pyrrolidinedithiocarbamate induces apoptosis in cerebellar granule cells: involvement of AP-1 and MAP kinases. Neurochem Int. 2003 Jul;43(1):31-8. PubMed PMID: 12605880.
18: Németh ZH, Deitch EA, Szabó C, Haskó G. Pyrrolidinedithiocarbamate inhibits NF-kappaB activation and IL-8 production in intestinal epithelial cells. Immunol Lett. 2003 Jan 2;85(1):41-6. PubMed PMID: 12505195.
19: Watanabe T, Yoshizumi M, Akishita M, Eto M, Toba K, Hashimoto M, Nagano K, Liang YQ, Ohike Y, Iijima K, Sudoh N, Kim S, Nakaoka T, Yamashita N, Ako J, Ouchi Y. Induction of nuclear orphan receptor NGFI-B gene and apoptosis in rat vascular smooth muscle cells treated with pyrrolidinedithiocarbamate. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1738-44. PubMed PMID: 11701459.
20: Kanekura T, Higashi Y, Kanzaki T. Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells. Cancer Lett. 2000 Dec 20;161(2):177-83. PubMed PMID: 11090967.